Psilocybin: crystal structure solutions enable phase analysis of prior art and recently patented examples
Alexander M. Sherwood, Robert B. Kargbo, Kristi W. Kaylo, Nicholas V. Cozzi, Poncho Meisenheimer, James A. Kaduk
Acta Crystallographica Section C Structural Chemistry December 20, 2021 DOI: 10.1107/s2053229621013164 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Crystallographic analysis Peer reviewed |
|---|---|
| Population | Bulk psilocybin samples produced between 1963 and 2021 |
| Topics | Psilocybin |
| Citations | 10 |
| Key points | All published psilocybin diffraction data can be explained by three well-defined crystal forms—Hydrate A, Polymorph A, and Polymorph B—with no additional forms required. |
Abstract
Psilocybin {systematic name: 3-[2-(dimethylamino)ethyl]-1 H -indol-4-yl dihydrogen phosphate} is a zwitterionic tryptamine natural product found in numerous species of fungi known for their psychoactive properties. Following its structural elucidation and chemical synthesis in 1959, purified synthetic psilocybin has been evaluated in clinical trials and has shown promise in the treatment of various mental health disorders. In a recent process-scale crystallization investigation, three crystalline forms of psilocybin were repeatedly observed: Hydrate A, Polymorph A, and Polymorph B. The crystal structure for Hydrate A was solved previously by single-crystal X-ray diffraction. This article presents new crystal structure solutions for the two anhydrates, Polymorphs A and B, based on Rietveld refinement using laboratory and synchrotron X-ray diffraction data, and density functional theory (DFT) calculations. Utilizing the three solved structures, an investigation was conducted via Rietveld method (RM) based quantitative phase analysis (QPA) to estimate the contribution of the three different forms in powder X-ray diffraction (PXRD) patterns provided by different sources of bulk psilocybin produced between 1963 and 2021. Over the last 57 years, each of these samples quantitatively reflect one or more of the hydrate and anhydrate polymorphs. In addition to quantitatively evaluating the composition of each sample, this article evaluates correlations between the crystal forms present, corresponding process methods, sample age, and storage conditions. Furthermore, revision is recommended on characterizations in recently granted patents that include descriptions of crystalline psilocybin inappropriately reported as a single-phase `isostructural variant.' Rietveld refinement demonstrated that the claimed material was composed of approximately 81% Polymorph A and 19% Polymorph B, both of which have been identified in historical samples. In this article, we show conclusively that all published data can be explained in terms of three well-defined forms of psilocybin and that no additional forms are needed to explain the diffraction patterns.
Citations in the library
Cited by 10
- The Emergence of Psilocybin in Psychiatry and Neuroscience Pharmaceuticals April 9, 2025
- Conformational Landscape and Properties of Psilocybin: A Computational Approach ChemistrySelect October 4, 2022
- Psilocybin: Characterization of the Metastable Zone Width (MSZW), Control of Anhydrous Polymorphs, and Particle Size Distribution (PSD) ACS Omega February 7, 2022
- Molecular Structure, Reactivity and Spectroscopic Properties of Hallucinogens Psilocybin, Mescaline and their Derivatives – A Computational Study Letters in Applied NanoBioScience September 17, 2022
- A Modern Overview of the Potential Therapeutic Effects of Psilocybin in the Treatment of Depressive Disorders, Treatment-Resistant Depression, and End-of-Life Distress Cureus March 17, 2025
and 5 more in the library
Cites 13
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance Psychopharmacology July 7, 2006
- Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study Journal of Psychopharmacology January 13, 2015
- Psilocybin und Psilocin, zwei psychotrope Wirkstoffe aus mexikanischen Rauschpilzen Helvetica Chimica Acta 1959
- Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults Clinical Pharmacokinetics March 28, 2017
and 8 more in the library